Aviragen and Vaxart Amend Terms of Merger Agreement

Genetics Investing

Aviragen Therapeutics (NASDAQ:AVIR) and Vaxart announced that the companies have agreed to amend the terms of their previously announced merger agreement to increase the proposed ownership percentage of Aviragen stockholders of the combined company. As quoted in the press release: Wouter Latour, M.D., Chief Executive Officer of Vaxart, Inc., said, “The amended terms reflect our …

As quoted in the press release:

Wouter Latour, M.D., Chief Executive Officer of Vaxart, Inc., said, “The amended terms reflect our commitment to completing the transaction with Aviragen. Our Board and management believe in the strategic value of the merger and we look forward to creating meaningful value for all stockholders.”

Click here to read the full press release.

aviragen therapeutics merger therapeutics Genetics Investing